Phase II Trial of Consolidative Thoracic Radiotherapy for ES-SCLC After Standard Care of Chemo-immunotherapy

This is an open-label, single arm Phase II study designed to evaluate the efficacy and safety of thoracic radiotherapy for extensive-stage small-cell lung cancer treated with PD-1/PD-L1 plus etoposide platinum followed by PD-1/PD-L1 maintenance therapy

Trial Details

NCT ID
NCT05552846
Phase
NA
Sponsor
Ruijin Hospital
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • thoracic radiotherapy
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

  • Age between18 years and 80 years at time of study entry
  • ECOG performance status of 0 or 1
  • Body weight \>30 kg
  • Adequate bone marrow, liver and kidney function

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →